agalsidase alfa
Selected indexed studies
- Agalsidase Alfa. (, 2006) [PMID:30601613]
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. (J Med Genet, 2024) [PMID:37940383]
- Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. (J Med Genet, 2018) [PMID:29437868]
_Worker-drafted node — pending editorial review._
Connections
agalsidase alfa is a side effect of
Sources
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. (2024) pubmed
- A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. (2025) pubmed
- Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. (2018) pubmed
- Agalsidase Alfa. (2006) pubmed
- Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy. (2025) pubmed
- Agalsidase Beta. (2006) pubmed
- Agalsidase alfa: a review of its use in the management of Fabry disease. (2012) pubmed
- Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data. (2024) pubmed
- Agalsidase alfa: specific treatment for Fabry disease. (2002) pubmed
- Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease. (2002) pubmed